SRR2016976
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.410
- ALLOGRAFT_REJECTION+0.350
- COAGULATION+0.340
- HEDGEHOG_SIGNALING+0.290
- UV_RESPONSE_DN+0.290
- COMPLEMENT+0.270
- APICAL_JUNCTION+0.250
- IL6_JAK_STAT3_SIGNALING+0.250
- INFLAMMATORY_RESPONSE+0.250
- MYOGENESIS+0.250
Top 10 suppressed
- MYC_TARGETS_V1-0.650
- E2F_TARGETS-0.630
- G2M_CHECKPOINT-0.590
- MYC_TARGETS_V2-0.580
- OXIDATIVE_PHOSPHORYLATION-0.540
- DNA_REPAIR-0.500
- MTORC1_SIGNALING-0.370
- UV_RESPONSE_UP-0.280
- MITOTIC_SPINDLE-0.270
- ADIPOGENESIS-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R132 | — | — | 0.929 |
| 2 | 895018d4-b355-4339-8c60-186478ae6551 | — | — | 0.908 |
| 3 | cbd54c6f-2634-4ac6-ba5a-73cb4680867a | — | — | 0.895 |
| 4 | TCGA-S2-AA1A-01A-12R-A39D-07 | — | cohortA1 | 0.888 |
| 5 | 1b192a49-01cb-4459-a7a7-fdebe428f386 | — | — | 0.885 |
| 6 | 59f108c6-677f-4cf2-89fd-6bd15133dd6f | — | — | 0.884 |
| 7 | 20020074.LumA | — | A | 0.881 |
| 8 | 20040019.LumA | — | A | 0.881 |
| 9 | MDT-AP-3282 | Med | Medulloblastoma | 0.881 |
| 10 | MNG47 | — | — | 0.881 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.410 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.350 | Idelalisib | — uncovered |
| COAGULATION | 0.340 | Binimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.290 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.290 | Inavolisib | — uncovered |
| COMPLEMENT | 0.270 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.250 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.250 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.250 | Idelalisib | — uncovered |
| MYOGENESIS | 0.250 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.230 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.210 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.200 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.190 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.170 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.130 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.130 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.110 | Inavolisib | — uncovered |